Skip to main content
. 2019 Nov 8;9:16379. doi: 10.1038/s41598-019-52852-9

Table 2.

Effect of FBS and HSA on IC50 values for ruxolitinib-dependent K562, HEL and SET-2 cell viability.

IC50 (μM)
Cell type 10% FBS 80 μM HSA 8 μM HSA 0.8 μM HSA 0.08 μM HSA no HSA
K562 >10 >10 >10 >10 >10 >10
HEL 4.7 ± 1.0 4.1 ± 0.8 3.1 ± 0.6 2.2 ± 0.5 1.7 ± 0.4 1.0 ± 0.3
SET-2 0.15 ± 0.04 0.10 ± 0.03 0.033 ± 0.005 0.032 ± 0.004 0.035 ± 0.008 0.033 ± 0.008